|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4,
451-457 (2006)
DOI: 10.1177/1076029606293430
Circulated Activated Platelets and Increased Platelet Reactivity in Patients With Behçet’s Disease
Servet Akar
Department of Internal Medicine, Division of Romatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Mehmet Ali Özcan
Department of Internal Medicine, Division of Hematology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Halil Ate
Department of Internal Medicine, Division of Hematology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
O uz Gürler
Department of Internal Medicine, Division of Romatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Inci Alacacioglu
Department of Internal Medicine, Division of Hematology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
G. Hayri Özsan
Department of Internal Medicine, Division of Hematology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Nurullah Akkoç
Department of Internal Medicine, Division of Romatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Sebnem Özkan
Department of Dermatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Fatih Demirkan
Department of Internal Medicine, Division of Hematology, School of Medicine, Dokuz Eylul University, Izmir, Turkey, fatih.demirkan{at}deu.edu.tr
Fatos Onen
Department of Internal Medicine, Division of Romatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Behçet’s disease (BD) is a multisystem disorder. Venous as well as arterial thrombosis is a common complication of BD but exact pathogenetic mechanism of the thrombotic tendency is not well known. This study aimed to evaluate circulating activated platelets and platelet reactivity in Behçet’s patients. Twenty-two Behçet’s patients (4 female, 18 male; mean age 38.6 ± 10.9 years) and 20 control subjects (8 female, 12 male; mean age 38.8 ± 9.4 years) were included. Those patients who had hypertension, hyperlipidemia, peripheral or coronary artery disease, hepatic or renal function abnormality, and who were using aspirin and other platelet-active drugs were excluded. Platelet activity and reactivity to adenosine diphosphate (ADP) were measured by whole blood flow cytometry. We assessed markers of platelet degranulation (P-selectin; CD62P) and the activated glycoprotein IIb/IIIa receptor (PAC1 binding to fibrinogen binding site) before and after stimulation with ADP. Platelet P-selectin expression was not significantly different between patients and control subjects both at baseline (p=0.420) and after stimulation (p=0.56). Baseline (p=0.001) and ADP-stimulated (p=0.003) PAC1 binding was significantly higher in Behçet’s patients than in the control group. Clinical activity has no effect on P-selectin expression and PAC1 binding. There is evidence of platelet activity and hyperreactivity in patients with BD and this may contribute to a prothrombotic state. In addition to aspirin, other antiplatelet drugs may be useful in the prevention and treatment of thrombosis in Behçet’s patients.
Key Words: Behçet’s disease • Platelet activity • Platelet reactivity • Platelet degranulation • Glycoprotein IIb/IIIa receptor
References
- Yurdakul S, Hanmuryudan V, Yazici H. Behçet's syndrome. Curr Opin Rheumatol 2004; 16: 38-38.[CrossRef][Medline]
[Order article via Infotrieve]
- Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341(17): 1284-1284.[Free Full Text]
- Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behçet's disease. J Rheumatol 1992; 19: 402-402.[ISI][Medline]
[Order article via Infotrieve]
- Kiraz S, Ertenli I, Ozturk MA, et al. Pathological haemostasis and "prothrombotic state" in Behçet's disease. Thromb Res 2002; 105(2): 125-125.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Gul A. Behçet's disease: An update on the pathogenesis. Clin Exp Rheumatol 2001; 19(Suppl 24): S6-S6.[ISI][Medline]
[Order article via Infotrieve]
- Kosar A, Mustafa O, Haznedaroglu IC, Karaaslan Y. Hemostatic parameters in Behçet's disease: A reappraisal. Rheumatol Int 2002; 22: 9-9.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Espinosa G, Font J, Tassies D, et al. Vascular involvement in Behçet's disease: Relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112: 37-37.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Akarsu M, Demirkan F, Özsan GH, et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease. Am J Hematol 2001; 68: 225-225.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Sengul N, Demirer S, Yerdel MA, et al. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement. World J Surg 2000; 24: 1584-1584.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Haim S, Brook JG, Gilhar A, et al. Platelet function in Behçet's disease. J Dermatol 1984; 11(2): 117-117.[Medline]
[Order article via Infotrieve]
- Wilson AP, Efthimiou J, Betteridge DJ. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome. Eur J Clin Invest 1988; 18(4): 410-410.[ISI][Medline]
[Order article via Infotrieve]
- Nakano H, Oka H, Matsuda T, et al. Spontaneous platelet aggregation in patients with Behçet's disease by using laser-light scattering aggregometer. Adv Exp Med Biol 2003; 528: 437-437.[ISI][Medline]
[Order article via Infotrieve]
- Tunc SE, Aksu K, Keser G, et al. Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet's patients. Rheumatol Int 2005; 25: 326-326.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Schmitz G, Rothe G, Ruf A, et al. European working group on clinical cell analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-885.[ISI][Medline]
[Order article via Infotrieve]
- Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6(5): 342-342.[CrossRef][Medline]
[Order article via Infotrieve]
- Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow cytometry. Methods 2000; 21(3): 259-259.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Andre P. P-selectin in haemostasis. Br J Haematol 2004; 126: 298-298.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335 (8697): 1078-1078.[ISI][Medline]
[Order article via Infotrieve]
- Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70(1): 307-307.[Abstract/Free Full Text]
- Payrastre B, Missy K, Trumel C, et al. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 2000; 60(8): 1069-1069.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm. Blood 1998; 91(8): 2645-2645.[Free Full Text]
- Peerschke EI. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb Haemost 1995; 73 (5): 862-862.[ISI][Medline]
[Order article via Infotrieve]
- Stathakis NE, Economopoulos TC, Papayannis AG, Thomopoulos D. Platelet function, blood coagulation and fibrinolysis in Behçet's syndrome. Blut 1977; 34(3): 215-215.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Thompson NT, Scrutton MC, Wallis RB. Particle volume changes associated with light transmittance changes in the platelet aggregometer: Dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986; 41(5): 615-615.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Plow EF, Pierschbacher MD, Ruoslahti E, et al. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82(23): 8057-8057.[Abstract/Free Full Text]
- Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-11877.[Abstract/Free Full Text]
- Michelson AD, Benoit SE, Kroll MH, et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994; 83 (12): 3562-3562.[Abstract/Free Full Text]
- Haznedaroglu E, Karaaslan Y, Buyukasik Y, et al. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis 2000; 59(1): 61-61.[Abstract/Free Full Text]
- Hizli N, Sahin G, Sahin F, et al. Plasma prostacyclin levels in Behçet's disease. Lancet 1985; 1(8443): 1454-1454.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Haznedaroglu IC, Dundar S, Kiraz S. Eicosanoids in the prethrombotic state of Behçet's disease. Thromb Res 1995; 80(5): 445-445.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26(7): 1665-1665.[Abstract]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
